Tuesday, April 15, 2014 12:59:58 AM
Mr. Grande said, "The acquisition of Hall of Fame, and our subsequent marketing of its products later this year, will help to round-out the product line by adding a premium tea and energy drink to the other brands that Randy [Hudson] and I have acquired for our holding company and for the benefit of our shareholders. Moreover, I am very eager to work with Mr. Johnson and with Hall of Fame's co-founder and the developer of the Atomic Dogg product, not only in this company, but in some of the other companies that Randy and I control. As we have tried in past to make clear, with this company, and with our other companies, the administrative clean-up of the companies is essential before we can move on to marketing the company's products, and, in the case of some of the companies, their services. This will only serve to build a strong foundation from which we can build and to avoid the mistakes made by each company's former senior executive management."
Mr. Hudson said, "Mike [Grande] and I have our work cut out for us; particularly, to bring Hall of Fame current in its administrative obligations with OTC Markets and Depository Trust Company. Once our administrative tasks are complete, we can begin to focus on the reintroduction of Hall of Fame's products. In addition, we expect to have Hall of Fame's interim website up-and-running by 7 February."
Fame intends to reintroduce its products on a limited basis in Upstate New York and Las Vegas by the end of the third calendar quarter of 2014, and, thereafter, to offer its products in select U. S. markets by mid-year 2015.
Mr. Grande will serve as the company's Chairman, President, and Chief Executive Officer, and Mr. Hudson will serve as its Vice-Chairman. In addition to the other officers and directors, Mr. Johnson will remain on Fame's Board of Directors, and, Mr. Johnson will also serve on the Board of Directors of Hudson and Grande, Fame's parent company.
Fame's shareholders and investors are welcome to inquire of the company's development by calling Mr. Grande at (585) 967-3198 or Mr. Hudson at (585) 329-3581.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM